KO

KOREAN DRUG CO., LTD.

Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.

014570 | KO

Overview

Corporate Details

ISIN(s):
KR7014570006
LEI:
Country:
South Korea
Address:
경기도 이천시 신둔면 원적로 69-10, 이천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Korean Drug Co., Ltd. is an established pharmaceutical company with over 50 years of experience in developing, manufacturing, and marketing therapeutic drugs. The company's portfolio includes both prescription (ETC) medicines for various conditions and over-the-counter (OTC) products, such as its 'Geunalen' brand of painkillers. Leveraging state-of-the-art production facilities and proprietary technology, the company produces a range of finished pharmaceutical products, and its offerings may also extend to health supplements and medical supplies. The company is committed to developing high-quality medicines for public health.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-13 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.2 KB
2025-08-11 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.5 KB
2025-07-02 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-06-30 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.6 KB
2025-06-05 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-06-02 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1019.2 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.7 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.6 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 18.4 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 444.5 KB
2025-03-06 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.3 KB
2025-03-04 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.5 KB
2025-02-26 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 102.6 KB

Automate Your Workflow. Get a real-time feed of all KOREAN DRUG CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOREAN DRUG CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOREAN DRUG CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Idorsia Ltd Logo
Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.
Switzerland
IDIA
IGC Pharma, Inc. Logo
Clinical-stage pharma creating Alzheimer's therapies & AI-powered diagnostics.
United States of America
IGC
IL DONG PHARMACEUTICAL CO., LTD. Logo
Develops & manufactures pharmaceuticals, APIs, and offers CMO services for various diseases.
South Korea
249420
ILSUNG IS CO., LTD. Logo
Develops pharmaceuticals like antibiotics and anesthetics, expanding into CNS and GI therapies.
South Korea
003120
ILYANG PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.
South Korea
007570
I-Mab Logo
A clinical-stage biopharma developing immuno-oncology agents and bispecific antibodies for cancer.
United States of America
IMAB
ImageneBio, Inc. Logo
A clinical-stage biopharma pioneering therapies for immune & inflammatory diseases.
United States of America
IMA
IM Cannabis Corp. Logo
International producer of medical-grade cannabis for patients and providers in Israel and Germany.
United States of America
IMCC
Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.